These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31671446)

  • 41. Interconnected clusters of invasive meningococcal disease due to
    Miglietta A; Fazio C; Neri A; Pezzotti P; Innocenti F; Azzari C; Rossolini GM; Moriondo M; Nieddu F; Iannazzo S; D'Ancona F; Maraglino FP; Guerra R; Rezza G; Voller F; Stefanelli P
    Euro Surveill; 2018 Aug; 23(34):. PubMed ID: 30153883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt.
    Chippaux JP; Campagne G; Djibo S; Cissé L; Hassane A; Kanta I
    Ann Trop Med Parasitol; 1999 Jul; 93(5):505-10. PubMed ID: 10690246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000.
    Djibo S; Nicolas P; Alonso JM; Djibo A; Couret D; Riou JY; Chippaux JP
    Trop Med Int Health; 2003 Dec; 8(12):1118-23. PubMed ID: 14641847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.
    Mohammed I; Obineche EN; Onyemelukwe GC; Zaruba K
    J Infect; 1984 Sep; 9(2):190-6. PubMed ID: 6438244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
    Carod Artal FJ
    Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.
    Martinelli D; Fortunato F; Cappelli MG; Cozza V; Chironna M; Prato R
    J Immunol Res; 2015; 2015():710656. PubMed ID: 26351649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135.
    Boisier P; Djibo S; Sidikou F; Mindadou H; Kairo KK; Djibo A; Goumbi K; Chanteau S
    Trop Med Int Health; 2005 May; 10(5):435-43. PubMed ID: 15860090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
    De Wals P
    Expert Rev Vaccines; 2006 Apr; 5(2):269-75. PubMed ID: 16608426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis serogroup C in Africa: recommendations from a WHO expert consultation.
    Wkly Epidemiol Rec; 2015 Nov; 90(47):633-6. PubMed ID: 26591025
    [No Abstract]   [Full Text] [Related]  

  • 50. Outbreak of Neisseria meningitidis serogroup C outside the meningitis belt-Liberia, 2017: an epidemiological and laboratory investigation.
    Bozio CH; Vuong J; Dokubo EK; Fallah MP; McNamara LA; Potts CC; Doedeh J; Gbanya M; Retchless AC; Patel JC; Clark TA; Kohar H; Nagbe T; Clement P; Katawera V; Mahmoud N; Djingarey HM; Perrocheau A; Naidoo D; Stone M; George RN; Williams D; Gasasira A; Nyenswah T; Wang X; Fox LM;
    Lancet Infect Dis; 2018 Dec; 18(12):1360-1367. PubMed ID: 30337259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
    Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
    Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.
    Tartof S; Cohn A; Tarbangdo F; Djingarey MH; Messonnier N; Clark TA; Kambou JL; Novak R; Diomandé FV; Medah I; Jackson ML
    PLoS One; 2013; 8(5):e63605. PubMed ID: 23671685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [From genomics to surveillance, prevention and control: new challenges for the African meningitis belt].
    Alonso JM; Bertherat E; Perea W; Borrow R; Chanteau S; Cohet C; Dodet B; Greenwood B; LaForce FM; Muros-Le Rouzic E; Teyssou R; Ouédraogo-Traoré R; Sow I
    Bull Soc Pathol Exot; 2006 Dec; 99(5):404-8. PubMed ID: 17253061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meningitis outbreak in Niger is an urgent warning.
    Burki T
    Lancet Infect Dis; 2015 Sep; 15(9):1011. PubMed ID: 26333332
    [No Abstract]   [Full Text] [Related]  

  • 56. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.
    Caini S; Beck NS; Yacouba H; Maiga I; Chaibou I; Hinsa I; Adakal A; Issoufou A; Kim SH; Pezzoli L
    Vaccine; 2013 Mar; 31(12):1597-603. PubMed ID: 23337027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.
    Borrow R; Alarcón P; Carlos J; Caugant DA; Christensen H; Debbag R; De Wals P; Echániz-Aviles G; Findlow J; Head C; Holt D; Kamiya H; Saha SK; Sidorenko S; Taha MK; Trotter C; Vázquez Moreno JA; von Gottberg A; Sáfadi MA;
    Expert Rev Vaccines; 2017 Apr; 16(4):313-328. PubMed ID: 27820969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningitis trends in Niger 2008-2015: a secondary data analysis.
    Djibo I; Yanogo PK; Kaboré J; Sawadogo B; Alkassoum I; Antara S; Meda N
    Med Sante Trop; 2019 Nov; 29(4):435-439. PubMed ID: 31885001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
    Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
    Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.